By Fineline Cube 
China-based Eastenova (Chengdu) Biotechnology Co., Ltd. this week made an initial public offering (IPO) to the Hong Kong Stock Exchange. Key details, including the unit price, remain undisclosed at this stage. CCB International is acting as the sole sponsor for the offering.
Company Overview
Founded in 2016, Eastenova is dedicated to the research and development, manufacturing, and commercialization of regenerative medicine medical devices and foods for special medical purpose (FSMP). The company’s regenerative medicine material pipeline includes 13 injectable candidates and 8 dressings/patches. Its FSMP pipeline comprises two approved products: XIQIN, a pre-surgery carbohydrate supplement, and Xihongyuan, an electrolyte supplement.-Fineline Info & Tech